CalciMedica, Inc. (NASDAQ:CALC) Short Interest Up 35.0% in February

CalciMedica, Inc. (NASDAQ:CALC) was the target of a significant growth in short interest during the month of February. As of February 15th, there was short interest totalling 93,300 shares, a growth of 35.0% from the January 31st total of 69,100 shares. Based on an average daily volume of 40,600 shares, the days-to-cover ratio is presently 2.3 days. Currently, 1.3% of the shares of the company are short sold.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its position in CalciMedica by 51.2% in the third quarter. Geode Capital Management LLC now owns 66,553 shares of the company’s stock worth $295,000 after acquiring an additional 22,525 shares in the last quarter. Atria Investments Inc raised its position in CalciMedica by 136.5% in the third quarter. Atria Investments Inc now owns 26,503 shares of the company’s stock worth $117,000 after acquiring an additional 15,296 shares in the last quarter. PVG Asset Management Corp purchased a new position in CalciMedica in the third quarter worth $67,000. Millennium Management LLC raised its position in CalciMedica by 30.5% in the fourth quarter. Millennium Management LLC now owns 72,057 shares of the company’s stock worth $255,000 after acquiring an additional 16,824 shares in the last quarter. Finally, Cetera Investment Advisers raised its position in CalciMedica by 37.1% in the fourth quarter. Cetera Investment Advisers now owns 16,873 shares of the company’s stock worth $60,000 after acquiring an additional 4,566 shares in the last quarter.

CalciMedica Price Performance

CalciMedica stock opened at $2.20 on Tuesday. CalciMedica has a 12 month low of $1.91 and a 12 month high of $6.27. The business has a 50 day simple moving average of $2.78 and a 200-day simple moving average of $3.46. The stock has a market capitalization of $29.66 million, a PE ratio of -2.04 and a beta of 1.18.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of CalciMedica in a research note on Thursday, November 14th.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.